Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.
暂无分享，去创建一个
S. Jagannath | S. Lonial | R. Vij | P. Moreau | J. Kaufman | X. Leleu | T. Facon | J. Harousseau | A. Singhal | A. Mazumder | J. Fry